Institutional shares held 87.9 Million
673K calls
865K puts
Total value of holdings $1.44B
$11M calls
$14.1M puts
Market Cap $1.14B
76,011,800 Shares Out.
Institutional ownership 115.67%
# of Institutions 320


Latest Institutional Activity in NTLA

Top Purchases

Q3 2024
Signal Advisors Wealth, LLC Shares Held: 46.4K ($695K)
Q3 2024
Harbor Capital Advisors, Inc. Shares Held: 79.2K ($1.19M)
Q3 2024
Steel Peak Wealth Management LLC Shares Held: 19.1K ($286K)
Q3 2024
Sg Americas Securities, LLC Shares Held: 24.1K ($362K)
Q3 2024
Hennion & Walsh Asset Management, Inc. Shares Held: 53.7K ($805K)

Top Sells

Q3 2024
Capital Advisors Inc Shares Held: 204K ($3.05M)
Q3 2024
Raymond James & Associates Shares Held: 178K ($2.67M)
Q3 2024
New York State Common Retirement Fund Shares Held: 28.4K ($425K)
Q3 2024
Commonwealth Equity Services, LLC Shares Held: 24.4K ($366K)
Q3 2024
Gamma Investing LLC Shares Held: 217 ($3.25K)

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at NTLA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
475K Shares
From 20 Insiders
Grant, award, or other acquisition 458K shares
Exercise of conversion of derivative security 17.6K shares
Sell / Disposition
57.6K Shares
From 10 Insiders
Open market or private sale 57.6K shares

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA